SCHEMBL15969826

SCHEMBL15969826

COc1c(C(=O)NC(C)c2cccc(N3CCN(C(=O)OC(C)(C)C)CC3)c2)c2ccccc2n(C)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GFER P55789 1/20 0.42
SOS1 Q07889 1/20 0.41
SGMS1 Q86VZ5 1/20 0.40
SGMS2 Q8NHU3 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
NR2F2 P24468 1/20 0.40
HTT P42858 1/20 0.40
ABCB1 P08183 1/20 0.39
ROCK2 O75116 1/20 0.39
MAPT P10636 2/20 0.38
GPR119 Q8TDV5 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
BACE1 P56817 2/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14848315 1.00 L3MBTL1 (0.47) L3MBTL1MEN1KMT2AGFERSOS1
SCHEMBL14848313 0.85 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AGFERMAPT
SCHEMBL15970038 0.85 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AGFERMAPT
SCHEMBL14830813 0.80 L3MBTL1 (0.57) L3MBTL1MEN1KMT2AGFERSMN1; SMN2
SCHEMBL14848319 0.79 L3MBTL1 (0.50) L3MBTL1MEN1KMT2AGFERNPC1
SCHEMBL14848291 0.79 L3MBTL1 (0.50) L3MBTL1MEN1KMT2AGFERNPC1
SCHEMBL15969612 0.78 L3MBTL1 (0.55) L3MBTL1MEN1KMT2AHTTROCK2
SCHEMBL14848312 0.78 L3MBTL1 (0.55) L3MBTL1MEN1KMT2AHTTROCK2
SCHEMBL15969583 0.76 L3MBTL1 (0.54) L3MBTL1MEN1KMT2AGFERSMN1; SMN2
SCHEMBL15969584 0.76 L3MBTL1 (0.54) L3MBTL1MEN1KMT2AGFERSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL L3MBTL1 3619/4885MEN1 4291/4885KMT2A 1068/4885
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL L3MBTL1 3619/4885MEN1 4291/4885KMT2A 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.